Some mutations have been proposed as diagnostic genetic biomarkers (PTPRD) or as prognostic biomarkers (KLF2 and NOTCH2) for NMZL [9], but need validation for their clinical utility. The gene discussed is PTPRD; the disease is nodal marginal zone B-cell lymphoma.